Comparative Pharmacology
Head-to-head clinical analysis: CHOLEBRINE versus OMNIPAQUE 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEBRINE versus OMNIPAQUE 12.
CHOLEBRINE vs OMNIPAQUE 12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholebrine is an iodinated contrast agent that attenuates X-rays, improving visualization of anatomical structures during imaging procedures.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
1-2 mCi (37-74 MBq) intravenously as a single dose for hepatobiliary scintigraphy.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 6-12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <5%.
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent